<p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在周一更新了其 2026 财年的盈利指引。该公司提供的每股收益（EPS）指引为 7.750-8.250，而市场共识预期为 8.010。该公司发布的收入指引为 17 亿至 18 亿美元，而市场共识收入预期为 18 亿美元。</p>
<p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
<h2>分析师评级调整</h2>
<p>多家券商对 HALO 发布了报告。Benchmark 将 Halozyme Therapeutics 的目标价从 75.00 美元上调至 90.00 美元，并在 2 月 19 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 将 Halozyme Therapeutics 的目标价从 90.00 美元上调至 95.00 美元，并在 4 月 29 日的研究报告中给予该公司 “买入” 评级。华尔街 Zen 在 2 月 21 日的研究报告中将 Halozyme Therapeutics 的评级从 “强烈买入” 下调至 “持有”。Weiss Ratings 在 2 月 24 日的研究报告中将 Halozyme Therapeutics 的评级从 “买入（b-）” 下调至 “持有（c）”。最后，TD Cowen 在 2 月 18 日的研究报告中重申了对 Halozyme Therapeutics 股票的 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，五位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 79.11 美元。</p>
<p><strong>查看我们关于 HALO 的最新研究报告</strong></p>
<h2>Halozyme Therapeutics 价格表现</h2>
<p>在周一的午盘交易中，纳斯达克：HALO 的股票上涨了 2.29 美元，达到了 66.41 美元。该公司的交易量为 2,869,627 股，而其平均交易量为 1,735,304 股。Halozyme Therapeutics 的 12 个月低点为 47.50 美元，12 个月高点为 82.22 美元。该公司的债务与股本比率为 43.89，流动比率为 4.66，速动比率为 3.66。该股票的市值为 78.7 亿美元，市盈率为 26.67，市盈增长比率为 0.26，贝塔值为 0.89。该公司的 50 日简单移动平均线为 65.86 美元，200 日简单移动平均线为 68.59 美元。</p>
<p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在 5 月 11 日周一发布了季度财报。这家生物制药公司报告的季度每股收益为 1.60 美元，超出市场共识预期的 1.54 美元，超出幅度为 0.06 美元。Halozyme Therapeutics 的股本回报率为 136.12%，净利润率为 22.69%。该公司在本季度的收入为 3.7671 亿美元，而分析师预期为 3.5860 亿美元。Halozyme Therapeutics 已将其 2026 财年的指引设定为每股收益 7.750-8.250。研究分析师平均预测 Halozyme Therapeutics 在当前年度的每股收益为 7.68 美元。</p>
<h2>Halozyme Therapeutics 的内部活动</h2>
<p>在相关消息中，首席执行官 Helen Torley 在 4 月 6 日周一出售了 10,000 股该股票，交易价格为 63.50 美元，总价值为 635,000.00 美元。出售完成后，首席执行官持有 767,780 股公司股票，价值约为 48,754,030 美元。此交易代表其持股比例减少了 1.29%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bernadette Connaughton 在 5 月 1 日周五出售了 1,625 股该股票，交易价格为 63.48 美元，总价值为 103,155.00 美元。出售完成后，该董事直接持有 38,498 股公司股票，价值约为 2,443,853.04 美元。这代表其持股比例减少了 4.05%。该出售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 90,482 股公司股票，价值为 6,073,942 美元。目前，内部人士持有该股票的比例为 2.50%。</p>
<h2>机构投资者对 Halozyme Therapeutics 的看法</h2>
<p>几家对冲基金和其他机构投资者最近增加或减少了对 HALO 的持股。Voloridge Investment Management LLC 在第三季度收购了 Halozyme Therapeutics 的新股份，价值 77,587,000 美元。Qube Research &amp; Technologies Ltd 在第二季度收购了 Halozyme Therapeutics 的新股份，价值 51,295,000 美元。Arrowstreet Capital Limited Partnership 在第三季度将其在 Halozyme Therapeutics 的持股增加了 29.5%。Arrowstreet Capital Limited Partnership 目前持有该生物制药公司 3,290,665 股股票，价值 241,337,000 美元，此前在上个季度又收购了 749,484 股。Royal London Asset Management Ltd.在第二季度将其在 Halozyme Therapeutics 的持股增加了 122.3%。Royal London Asset Management Ltd.目前持有该生物制药公司 1,101,912 股股票，价值 57,321,000 美元，此前在上个季度又收购了 606,236 股。最后，AQR Capital Management LLC 在第三季度将其在 Halozyme Therapeutics 的持股增加了 155.7%。AQR Capital Management LLC 目前持有该生物制药公司 968,511 股股票，价值 71,031,000 美元，此前在上个季度又收购了 589,711 股。机构投资者和对冲基金持有该公司 97.79% 的股票。</p>
<h2>Halozyme Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Halozyme Therapeutics, Inc 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，专注于新型药物输送技术的开发和商业化。成立于 1998 年，Halozyme 致力于通过其专有平台实现生物疗法的皮下给药。公司的核心使命是改善患者的获取和便利性，同时保持与传统给药途径相当或更好的疗效和安全性。</p>
<p>公司的旗舰技术 ENHANZE®基于重组人透明质酸酶 PH20（rHuPH20），这是一种暂时降解细胞外基质中透明质酸的酶。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Halozyme Therapeutics</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外下行，这三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Halozyme Therapeutics 吗？</h2>
<p>在考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
<p>虽然 Halozyme Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奥洛兹美医疗

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

IBBQ

标普生物技术 3 倍做多 - Direxion

<p>Halozyme Therapeutics（纳斯达克代码：HALO）更新了其 2026 财年的收益指引，预计每股收益在 7.750 至 8.250 之间，略低于市场共识预期的 8.010。收入指引设定在 17 亿至 18 亿美元之间，同样低于市场共识的 18 亿美元。分析师对该股票的评级各异，整体共识评级为 “持有”，目标价为 79.11 美元。近期交易中，股价上涨至 66.41 美元，市值为 78.7 亿美元。内部交易活动中，首席执行官 Helen Torley 出售了 10,000 股股票</p>

<p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 7.750-8.250 for the period, compared to the consensus estimate of 8.010. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.</p>
<div class="lb-trans"><p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在周一更新了其 2026 财年的盈利指引。该公司提供的每股收益（EPS）指引为 7.750-8.250，而市场共识预期为 8.010。该公司发布的收入指引为 17 亿至 18 亿美元，而市场共识收入预期为 18 亿美元。</p>
</div><p>Get <strong>Halozyme Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of brokerages have issued reports on HALO. Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 19th. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded Halozyme Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, February 21st. Weiss Ratings downgraded Halozyme Therapeutics from a &#34;buy (b-)&#34; rating to a &#34;hold (c)&#34; rating in a research report on Tuesday, February 24th. Finally, TD Cowen restated a &#34;buy&#34; rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $79.11.</p>
<div class="lb-trans"><p>多家券商对 HALO 发布了报告。Benchmark 将 Halozyme Therapeutics 的目标价从 75.00 美元上调至 90.00 美元，并在 2 月 19 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 将 Halozyme Therapeutics 的目标价从 90.00 美元上调至 95.00 美元，并在 4 月 29 日的研究报告中给予该公司 “买入” 评级。华尔街 Zen 在 2 月 21 日的研究报告中将 Halozyme Therapeutics 的评级从 “强烈买入” 下调至 “持有”。Weiss Ratings 在 2 月 24 日的研究报告中将 Halozyme Therapeutics 的评级从 “买入（b-）” 下调至 “持有（c）”。最后，TD Cowen 在 2 月 18 日的研究报告中重申了对 Halozyme Therapeutics 股票的 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，五位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 79.11 美元。</p>
</div><p><strong>View Our Latest Research Report on HALO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 HALO 的最新研究报告</strong></p>
</div><h2>Halozyme Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ:HALO traded up $2.29 during midday trading on Monday, hitting $66.41. The company had a trading volume of 2,869,627 shares, compared to its average volume of 1,735,304. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The stock has a market cap of $7.87 billion, a price-to-earnings ratio of 26.67, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The business's 50-day simple moving average is $65.86 and its 200-day simple moving average is $68.59.</p>
<div class="lb-trans"><p>在周一的午盘交易中，纳斯达克：HALO 的股票上涨了 2.29 美元，达到了 66.41 美元。该公司的交易量为 2,869,627 股，而其平均交易量为 1,735,304 股。Halozyme Therapeutics 的 12 个月低点为 47.50 美元，12 个月高点为 82.22 美元。该公司的债务与股本比率为 43.89，流动比率为 4.66，速动比率为 3.66。该股票的市值为 78.7 亿美元，市盈率为 26.67，市盈增长比率为 0.26，贝塔值为 0.89。该公司的 50 日简单移动平均线为 65.86 美元，200 日简单移动平均线为 68.59 美元。</p>
</div><p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $376.71 million during the quarter, compared to analysts' expectations of $358.60 million. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts predict that Halozyme Therapeutics will post 7.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Halozyme Therapeutics（纳斯达克股票代码：HALO - 获取免费报告）在 5 月 11 日周一发布了季度财报。这家生物制药公司报告的季度每股收益为 1.60 美元，超出市场共识预期的 1.54 美元，超出幅度为 0.06 美元。Halozyme Therapeutics 的股本回报率为 136.12%，净利润率为 22.69%。该公司在本季度的收入为 3.7671 亿美元，而分析师预期为 3.5860 亿美元。Halozyme Therapeutics 已将其 2026 财年的指引设定为每股收益 7.750-8.250。研究分析师平均预测 Halozyme Therapeutics 在当前年度的每股收益为 7.68 美元。</p>
</div><h2>Insider Activity at Halozyme Therapeutics</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的内部活动</h2>
</div><p>In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $63.50, for a total value of $635,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $48,754,030. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the sale, the director directly owned 38,498 shares of the company's stock, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 90,482 shares of company stock valued at $6,073,942. 2.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Helen Torley 在 4 月 6 日周一出售了 10,000 股该股票，交易价格为 63.50 美元，总价值为 635,000.00 美元。出售完成后，首席执行官持有 767,780 股公司股票，价值约为 48,754,030 美元。此交易代表其持股比例减少了 1.29%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Bernadette Connaughton 在 5 月 1 日周五出售了 1,625 股该股票，交易价格为 63.48 美元，总价值为 103,155.00 美元。出售完成后，该董事直接持有 38,498 股公司股票，价值约为 2,443,853.04 美元。这代表其持股比例减少了 4.05%。该出售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 90,482 股公司股票，价值为 6,073,942 美元。目前，内部人士持有该股票的比例为 2.50%。</p>
</div><h2>Institutional Investors Weigh In On Halozyme Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Halozyme Therapeutics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Voloridge Investment Management LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth $77,587,000. Qube Research &amp; Technologies Ltd acquired a new stake in Halozyme Therapeutics during the second quarter worth $51,295,000. Arrowstreet Capital Limited Partnership increased its stake in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company's stock worth $241,337,000 after acquiring an additional 749,484 shares during the last quarter. Royal London Asset Management Ltd. increased its stake in Halozyme Therapeutics by 122.3% during the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company's stock worth $57,321,000 after acquiring an additional 606,236 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Halozyme Therapeutics by 155.7% during the third quarter. AQR Capital Management LLC now owns 968,511 shares of the biopharmaceutical company's stock worth $71,031,000 after acquiring an additional 589,711 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近增加或减少了对 HALO 的持股。Voloridge Investment Management LLC 在第三季度收购了 Halozyme Therapeutics 的新股份，价值 77,587,000 美元。Qube Research &amp; Technologies Ltd 在第二季度收购了 Halozyme Therapeutics 的新股份，价值 51,295,000 美元。Arrowstreet Capital Limited Partnership 在第三季度将其在 Halozyme Therapeutics 的持股增加了 29.5%。Arrowstreet Capital Limited Partnership 目前持有该生物制药公司 3,290,665 股股票，价值 241,337,000 美元，此前在上个季度又收购了 749,484 股。Royal London Asset Management Ltd.在第二季度将其在 Halozyme Therapeutics 的持股增加了 122.3%。Royal London Asset Management Ltd.目前持有该生物制药公司 1,101,912 股股票，价值 57,321,000 美元，此前在上个季度又收购了 606,236 股。最后，AQR Capital Management LLC 在第三季度将其在 Halozyme Therapeutics 的持股增加了 155.7%。AQR Capital Management LLC 目前持有该生物制药公司 968,511 股股票，价值 71,031,000 美元，此前在上个季度又收购了 589,711 股。机构投资者和对冲基金持有该公司 97.79% 的股票。</p>
</div><h2>Halozyme Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.</p>
<div class="lb-trans"><p>Halozyme Therapeutics, Inc 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，专注于新型药物输送技术的开发和商业化。成立于 1998 年，Halozyme 致力于通过其专有平台实现生物疗法的皮下给药。公司的核心使命是改善患者的获取和便利性，同时保持与传统给药途径相当或更好的疗效和安全性。</p>
</div><p>The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.</p>
<div class="lb-trans"><p>公司的旗舰技术 ENHANZE®基于重组人透明质酸酶 PH20（rHuPH20），这是一种暂时降解细胞外基质中透明质酸的酶。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Halozyme Therapeutics</li>
<li>Before the Moon Base Gets Built, These 4 Companies Win</li>
<li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li>
<li>3 Stocks That Win If Inflation Surprises to the Downside</li>
<li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Halozyme Therapeutics</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外下行，这三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=HALO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Halozyme Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Halozyme Therapeutics 吗？</h2>
</div><p>Before you consider Halozyme Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
</div><p>While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Halozyme Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

奥洛兹美医疗（NASDAQ:HALO）发布 2026 财年盈利指引